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Objective: Laser-assisted intracytoplasmic sperm injection (LA-ICSI), also known as micro-opening or thinning of the zona pellucida (ZP) prior 
to ICSI, may help to reduce mechanical damage to the oocyte during the procedure. The aim of the present study was to evaluate and analyze 
the efficacy of our institutional LA-ICSI program, which features laser-assisted ZP thinning prior to ICSI, in comparison with conventional ICSI (C-
ICSI), performed on patients with different clinical characteristics.
Methods: Patients undergoing a total of 212 ICSI cycles were randomly divided into an LA-ICSI group (106 cycles) and a conventional ICSI group 
(106 cycles). To reduce tissue damage, we thinned the ZP by approximately 70%, using a laser, before ICSI. Patients thus treated formed the LA-
ICSI group. Comparisons included the morphological quality of transferred embryos, blastocyst development of the remaining embryos, and 
clinical pregnancy, in terms of ICSI method and patient characteristics.
Results: Fertilization, development of remaining embryos, and pregnancy rate were significantly higher in the LA-ICSI group compared with 
the C-ICSI group. Fertilization, embryonic development, and the pregnancy rate were all improved in younger patients (<38 years of age) and 
in those who underwent a low number of IVF-ET attempts (<3 trials). In addition, the pregnancy rate was increased in older patients. 
Conclusion: LA-ICSI may be useful in improving the chance of pregnancy in all ICSI patients.
Keywords: Intracytoplasmic Sperm Injection; Laser-assisted Intracytoplasmic Sperm Injection; In Vitro Fertilization-embryo Transfer; Zona Pel-
lucida Thinning; Clinical Outcome; Human
Introduction 
In the time since the first successful pregnancy after ICSI was re-
ported in 1992 [1], ICSI has become a routine method of fertilization 
if male factor infertility is evident, and the treatment is also used in 
instances of non-male factor infertility if repeated attempts at IVF-ET 
fail [2-5]. However, ICSI has several drawbacks. These include me-
chanical damage to the cytoplasmic membrane, the cytoskeleton, 
and the meiotic spindle that occurs during membrane penetration 
and sperm deposition [6,7]. In fact, oocyte degeneration and abnor-
mal fertilization constitute the principal reasons for the cancellation 
of assisted reproductive techniques (ART) cycles. Additionally, some 
oocytes are very fragile, and the zona pellucida can be very resistant 
to penetration, resulting in sudden breakage of the membrane dur-
ing ICSI [7-9]. To overcome these problems, several groups have de-
veloped piezo- or laser-assisted ICSI techniques (LA-ICSI). Piezo-ICSI, 
which uses a blunt injection needle operated by a piezo-electric de-
vice, efficiently prevents damage to both mouse and human oocytes 
[10,11]. However, this technique has become unpopular owing to a 
risk of mercury contamination and practical difficulties. Lasers have 
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already been used as convenient and safe tools in assisted hatching 
and pre-implantation genetic diagnosis (PGD). Rienzi et al. [12] re-
ported that LA-ICSI, featuring micro-opening or drilling of the ZP pri-
or to ICSI, reduced the degeneration rate of human oocytes and in-
creased embryo development rates in patients who had experienced 
prior ICSI failures caused by poor oocyte survival [13]. Several groups 
have reported similar results in selected patients with histories of 
poor ICSI outcomes, for whom only limited numbers of oocytes were 
available [13,14]. In addition, when used to overcome fertilization 
problems, laser-assisted ZP thinning prior to routine ICSI both im-
proved oocyte survival and increased the hatching rate in vitro [15]. 
However, the clinical utility of LA-ICSI remains controversial because 
comparisons of fertilization, embryo quality, and clinical outcomes 
have not been performed in the general patient populations eligible 
for routine ICSI. In addition, the study groups have had included few 
cases. Therefore, the objective of the present work was to evaluate 
the possible benefits of LA-ICSI, thus thinning of the ZP prior to ICSI, 
as part of a routine ICSI program in non-randomized patients. We 
compared the data with those collected from conventional ICSI (C-
ICSI) patients. The clinical outcomes of both groups were re-analyzed 
in terms of the age and history of female patients, to identify any pos-
sible clinical significance of laser use.
 
Methods
This study was approved by the Institutional Review Board of the 
CHA Gangnam Medical Center (Seoul, Korea) and was conducted be-
tween February and September of 2009. Patients experiencing a to-
tal of 212 ICSI cycles were randomly divided into two groups (106 cy-
cles of LA-ICSI and 106 cycles of C-ICSI). 
1. LA- and C-ICSI procedures
Starting on the third day of the cycle, controlled ovarian hyperstim-
ulation was achieved using recombinant FSH (rFSH; Gonal-F, Merck-
Serono, Modugno Bari, Italy). To prevent any premature LH surge, we 
employed a GnRH agonist (Lucrin, Abbott, Seoul, Korea) using the 
long protocol, or a GnRH antagonist (Cetorelix, Cetrotide, Merck-Se-
rono) given after 5-6 days of stimulation. Ovulation was triggered by 
the injection of 10,000 IU hCG (Profasi, Merck-Serono) when at least 
two follicles were over 18 mm in diameter. Transvaginal oocyte re-
trieval was performed 34-36 hours after hCG administration. 
For LA-ICSI, an oocyte was held with the polar body in the 12-o’clock 
position. The ZP was thinned by approximately 70% at the 3-o’clock 
position (where the injection needle was to penetrate) using a laser 
pulse 100 µ sec in duration (ZILOS-tk class I laser, Hamilton Thorne 
Research, Beverly, MA, USA). An ICSI needle was introduced into the 
oocyte through the pre-thinned region of the ZP, and the overall pro-
cess was termed LA-ICSI. The control group received conventional 
ICSI and was termed the C-ICSI group. After both C-ICSI and LA-ICSI, 
oocytes injected with a spermatozoon were incubated (under 5% 
CO2 and 5% O2, both v/v, and at 37°C) in drops of Quinn’s Advantage 
Cleavage medium (Sage, Trumbull, CT, USA) under oil.
2. Evaluation of oocyte integrity, fertilization, embryo 
development, and pregnancy 
Fertilization and degeneration of injected oocytes were monitored 
16-18 hours after ICSI. Fertilized embryos were transferred to drops 
of fresh cleavage medium. At day 3, embryo quality was graded into 
five levels based on the percentage of fragmentation and the num-
ber and size of blastomeres [14]; two or three embryos were selected 
for embryo transfer. After transfer to the uterus, the remaining em-
bryos were cultured to day 7 for evaluation of blastocyst formation. 
To artificially prepare the endometrium, E2 valerate (4-6 mg/day; Pro-
gynova, Schering, Bayer, New Zealand) was administrated and pro-
gesterone (100 mg/day; Samil Pharm. Co., Ltd., Seoul, Korea) was in-
jected when the endometrium attained 8 mm in thickness. Pregnan-
cy was evaluated by measurement of the serum β-hCG level 12 days 
after embryo transfer and a clinical pregnancy was defined as thep-
resence of a gestational sac with positive heart activity at 5-7 weeks.
3. Analysis of clinical outcomes by patient profiles
All clinical outcomes, including fertilization and degeneration rates, 
development of remaining embryos into blastocysts, clinical preg-
nancy rate and abortion rate were evaluated. First, clinical outcomes 
in the LA-ICSI and C-ICSI groups were compared among all patients. 
Second, the data were re-analyzed with respect to female age (<38 
years and ≥38 years). The age of patients was distinguished based 
on research results of a study that used laser for zona thining [16]. 
Last, the data were re-analyzed in terms of the number of prior IVF-
ET attempts (<3 and ≥3).
4. Statistical analysis
Unless otherwise specified, data are expressed as means±SE. Clini-
cal outcomes were analyzed using the chi-square test and Student’s 
t-test. A p<0.05 was considered to be statistically significant.
Results
1. Comparisons of the clinical outcomes of the LA-ICSI and 
C-ICSI groups 
The clinical profiles of patients in both groups are summarized in 
Table 1. The average age , sperm strict morphology using Kruger’s 
strict criteria and the cycle date of hCG injection were similar in both 
groups. Also, neither the E2 concentration on the day of hCG injection   http://dx.doi.org/10.5653/cerm.2011.38.3.148
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nor the total number of retrieved oocytes differed between groups. 
In C-ICSI patients, 941 MII oocytes retrieved from 106 cycles were in-
jected with sperm; 714 (75.9%) became fertilized and 40 (4.3%) de-
generated. A total of 953 MII oocytes retrieved from 106 cycles were 
injected in the LA-ICSI group; 777 (81.5%) became fertilized and 27 
(3.0%) degenerated. Figure 1 shows that, although the degeneration 
rate did not differ between groups, the fertilization rate in the LA-ICSI 
group was higher than that in the C-ICSI group (81.5% vs. 75.9%; 
p<0.05). Also, the blastocyst formation rate from embryos remain-
ing after transfer and the clinical pregnancy rate were significantly 
higher in the LA-ICSI group (36.2% and 50.0% vs. 29.1% and 30.2%, 
respectively; p<0.05), even though the number of transferred em-
bryos and the scores of such embryos at day 3 were similar in both 
groups. Use of LA-ICSI slightly increased the implantation rate, but 
the increase was not statistically significant. 
2. Comparisons of clinical outcomes of the LA-ICSI and C-ICSI 
groups with respect to female age 
To investigate the specific efficacy of LA-ICSI, the data from both 
groups were re-analyzed in terms of female age. As shown in Figure 
2, LA-ICSI showed improved pregnancy rates in both age groups 
(58.2% vs. 39.7% in those <38 years old; 35.9% vs. 13.2% in those 
≥38 years old, p<0.05) when compared with C-ICSI. In addition, LA-
ICSI increased the fertilization (81.9% vs. 74.4%, respectively; p<0.05) 
and developmental rates of the remaining embryos (38.4% vs. 30.8%, 
respectively; p<0.05) and also reduced the degeneration rate (2.1% 
vs. 4.1%) in younger females (<38 years of age) (Figure 2A) when 
compared to the C-ICSI group. LA-ISCI did not affect these parame-
ters in older patients ( ≥38 years of age) (Figure 2B). 
3. Comparisons of clinical outcomes of the LA-ICSI and C-ICSI 
groups in terms of repeated IVF failure
In the present study, 42 IVF-ICSI patients who had experienced re-
peated IVF failure (≥3 IVF-ET attempts) were divided into two groups 
and the clinical outcomes after C-ICSI and LA-ICSI were analyzed. As 
shown in Figure 3A, all clinical outcomes, including embryonic devel-
opment, clinical pregnancy, and implantation rates, were slightly high-
er in the LA-ICSI group than in the C-ICSI group (13.3% vs. 25.9%, 
30.0% vs. 50.0%, and 14.0% vs. 21.8%, respectively), but these differ-
ences were not significant. However, when the 170 ICSI cycles of pa-
tients with a low number of prior IVF-ET attempts were analyzed, fer-
tilization, embryonic development, and clinical pregnancy rates were 
significantly improved in the LA-ICSI group compared with the C-ICSI 
group (82.4% vs. 75.6%, 37.6% vs. 30.7%, and 50.0% vs. 30.2%; all 
p<0.05, respectively) (Figure 3B). 
 
Discussion
To overcome a low fertilization rate caused by oocyte degeneration 
or abnormal embryonic development [4,6], the ICSI procedure has 
been modified over the past 20 years to reduce mechanical oocyte 
damage. LA-ICSI either creates a hole in or thins the ZP [9], and this 
may permit easy entrance of the needle into oocytes that are abnor-
mal in terms of thickness or ZP resistance. Hence, many researchers 
have suggested that LA-ICSI can reduce the damage suffered by oo-
Table 1. Clinical profiles of the laser-assisted intracytoplasmic sperm injection (LA-ICSI) and conventional ICSI (C-ICSI) groups
C-ICSI LA-ICSI p-value
 Number of cycles  106 106 NS
 Average of sperm strict morphology (%)  3.9 3.8 NS
 Average age of females (yr)   35.8±0.4  35.8±0.4 NS
 E2 level (pg/mL) on the day of hCG injection 1,823.0±119.5 1,823.1±131.9 NS
 Total number of oocytes (oocytes/case) 1,165 (11±0.8) 1,162 (11.0±0.7) NS
 Cycle duration (day)   12.8±0.1 12.8±0.2 NS
 Number of MII oocytes (oocytes/case) 941 (8.9±0.6) 953 (9.0±0.5) NS
 Score of transferred embryos  3.5±0.1 3.6±0.1 NS
 Number of embryos transferred  2.6±0.1 2.7±0.1 NS
Values are presented as means ± SE.
NS, not significant.
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Figure 1. Comparison of clinical outcomes between the laser-assist-
ed intracytoplasmic sperm injection (LA-ICSI) and conventional ICSI 
(C-ICSI) groups. 
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cytes during ICSI, with consequent benefits for embryonic develop-
ment [14,17]. However, most prior studies used ZP penetration me-
thods or analyzed only small numbers of specific patients with poor 
ICSI histories. To date, the efficacy of LA-ICSI in patients of varying 
characteristics has not been well studied. In the present work, we 
conducted a prospective comparison (LA-ICSI vs. C-ICSI) on patients 
undergoing our routine ICSI procedure, which features a conjugated 
IVF-ET program, and next re-analyzed clinical outcomes in terms of 
patient age and the number of prior IVF-ET attempts. The results show 
that LA-ICSI may not mitigate damage to injected oocytes, but en-
hanced both the fertilization rate and blastocyst formation by residu-
al embryos. Although the scores of transferred embryos did not differ 
between groups, we hypothesized that the quality of embryos se-
lected for transfer in the LA-ICSI group may have been better than 
that of C-ICSI group embryos, resulting in a satisfactory clinical preg-
nancy rate (Figure 1). In fact, the implantation rate was not increased 
significantly and was only slightly improved in the LA-ICSI group. 
Laser drilling of the ZP is used principally for laser-assisted hatching 
(LAH). Although LAH may enhance embryo implantation by mechan-
ically facilitating the hatching process and permitting embryo-endo-
metrium contact, LAH is associated with the risks associated with all 
invasive approaches. Mantoudis et al. [18] developed a partial LAH 
technique involving ZP thinning without bleaching of the inner mem-
brane; the pregnancy rate improved significantly . LAH has also been 
offered to selected patients who were older, who had experienced 
prior IVF-ET failures, or who responded poorly to gonadotropins. As 
with LAH, LA-ICSI has been used to treat selected patients who failed 
previous ICSI cycles or who produced limited numbers of MII oocytes 
[12-14]. By re-analyzing patients with specific indications for LA-ICSI, 
we found that the technique significantly improved clinical outcomes 
in both older and younger females. However, LA-ICSI may not im-
prove clinical outcomes of patients with histories of prior IVF-ET fail-
ures (≥3 attempts); this was in contrast to the results in patients with 
fewer prior attempts (Figure 3). Several reports have indicated that 
opening of the ZP prior to ICSI, and assisted hatching before embryo 
transfer are associated with twin pregnancies [12,16,19-21]. Howev-
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Figure 2. Comparison of clinical outcomes between the laser-assisted intracytoplasmic sperm injection (LA-ICSI) and conventional ICSI (C-ICSI) 
groups in females of different age groups (A: <38 years old, B: ≥38 years old). 
ap<0.05.
Figure 3. Comparison of clinical outcomes between the laser-assisted intracytoplasmic sperm injection (LA-ICSI) and conventional ICSI (C-ICSI) 
groups according to the number of prior IVF-ET attempts (A: ≥3 attempts, B: <3 attempts). 
ap<0.05.
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er, in the present study, we did not fully penetrate the ZP before ICSI 
to avoid this problem. Our approach may thus not affect the multiple 
pregnancy rate. The results indicate that LA-ICSI is valuable in routine 
practice. 
In conclusion, LA-ICSI may reduce damage to oocytes during fertil-
ization, in turn leading to improved embryonic development. En-
hanced clinical outcomes after use of LA-ICSI were evident in select-
ed patients who had experienced repeated IVF failure, or who were 
older, as well as when all patients undergoing routine ICSI were eval-
uated as two unselected groups. Also, LA-ICSI is a simple procedure. 
Therefore, we suggest that the LA-ICSI procedure be used for all ICSI 
patients to improve clinical outcomes. 
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